GNI Group is implementing changes in the representative executive officer and executive appointments for its subsidiaries to strengthen its global strategy and management foundation. Ying Luo has been appointed as the new CEO, and Ryosuke Matsui has been added as Vice President, aiming to accelerate the integration of clinical development capabilities and TPD technology and enhance new drug development and management agility.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/2160-20260507-02.pdf","jir_short_summary":"GNI Group is implementing changes in the representative executive officer and executive appointments for its subsidiaries to strengthen its global strategy and management foundation. Ying Luo has been appointed as the new CEO, and Ryosuke Matsui has been added as Vice President, aiming to accelerate the integration of clinical development capabilities and TPD technology and enhance new drug development and management agility.","jir_summary":"### Strengthening of Executive Personnel and Management System\nGNI Group is carrying out changes in the representative executive officer and executive personnel of its subsidiaries, advancing organizational structure to promote growth toward a global pharma. Ying Luo has been appointed as the new CEO of Gyre Therapeutics, accelerating the integration of clinical development capabilities and TPD technology within the group. This aims to drive new drug development and improve management responsiveness. Ryosei Matsui has been additionally appointed as Vice President, responsible for maintaining and operating the group's management, establishing a dual-leadership system.\n\n### Future Strategies and Enhancement of Corporate Value\nThese personnel changes are aimed at improving the group's mid- to long-term corporate value, strengthening information disclosure and collaboration in both Japanese and U.S. markets. Ying Luo will lead global strategies and new drug development, while Ryosei Matsui will oversee finance and operations, enabling rapid decision-making and stabilizing management response in a rapidly changing business environment.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#GNIGroup, #ExecutiveChange, #JapanStocks","jir_key_figures":"Unknown\nUnknown\nUnknown","jir_meta_title":"\u3010GNI Group\u3011 Strengthening of the Representative Executive Officer System and Executive Appointments for Subsidiaries | May 2026","jir_meta_description":"GNI Group is implementing changes in the representative executive officer and executive personnel for its subsidiaries to promote its global strategy and management foundation. Detailed information is provided.","jir_og_title":"\u3010GNI Group\u3011 Executive Personnel Changes and Management System Enhancement | May 2026","jir_og_description":"GNI Group has made changes in the representative executive officer and executive personnel for its subsidiaries, aiming to promote its global strategy and strengthen its management foundation.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-44903","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n